to Mean Channel shift (MCS) of fluorescence intensity. Cut-off value used <strong>for</strong> positive FXM was 60 and75 <strong>for</strong> T and B cells respectively. We examined 262 crossmatches that were per<strong>for</strong>med during the period ofNovember-March <strong>2010</strong>.Results: A summary of FXM results and DSA is shown in Table 1. Of the 262 FXM, 8.8% were positivewith MCS>1<strong>00</strong> and had anti-HLA Abs; 35% of these appear to be due to anti-DP or DRB3 allele-specificantibodies and the remaining were due to weak DSA (MFI: 1<strong>00</strong>0-3<strong>00</strong>0). 44% (18/41) of positive FXM withMCS>1<strong>00</strong> were not associated with DSA (MFI cut-off value5<strong>00</strong>), FCXMs were per<strong>for</strong>med when donor cells were available (n=35). Outcomes werecompared overall and between FCXM- vs unsensitized groups.Results: Table 1[table1]Conclusions: When DSA is present, patients are more likely to experience AMR than unsensitizedpatients. Collectively, the DSA+/FCXM+ patients have more AMR and lower CrCL than DSA+/FCXMpatients.This latter group still has significant AMR compared to unsensitized patients. Thus,DSA+/FCXM- recipients represent a higher risk transplant than DSA- recipients. Nonetheless, ∼50% ofDSA+ recipients (whether FCXM + or -) were rejection free, meaning that certain donor:recipientincompatibilities are acceptable. Further studies should address which elements dictate good outcome.12-PA NOVEL HLA CLASS I SINGLE ANTIGEN BEAD PREPARATION ELIMINATES FALSEPOSITIVE REACTIONS ATTRIBUTED TO NATURAL ANTIBODIES – IN THE SERA OFNORMAL MALES AND PRE-TRANSPLANT PATIENTS.Nadim R. El-Awar 1 , Paul I. Terasaki 2 , Ali Hajeer 3 , Afzal Nikaein 4 , Matthew Averly 1 , Judy Hopfield 1 , AnhNguyen 1 . 1 Research II, One Lambda Inc., Canoga Park, CA, USA; 2 Terasaki Foundation Laboratory, LosAngeles, CA, USA; 3 King Fahad National Guard Hospital, Riyadh, Saudi Arabia; 4 Texas MedicalSpecialty, Inc., Dallas, TX, USA.Aim: Single antigen (SA) beads have been shown to produce “false” irrelevant reactions in the sera of nonimmunizednormal males. We tested a new bead preparation produced to eliminate these reactions.Methods: 30 normal sera and 46 sera from pre-transplant (pre-Tx) patients were tested with SA beads, EBtreated beads and Clean SA Beads (patent pending) - free of denatured class I antigens (One Lambda Inc.).All MFI values >1<strong>00</strong>0 of the adjusted and normalized trimmed mean were considered positive.Results: Examples of HLA class I specificities of normal male (A) and pre-Tx (B) sera are shown.Reactions of the Clean Beads become negative as compared to the reactions with SA beads and reactionswith the EB treated beads are positive indicating the antibodies target cryptic epitopes. For example.,B0702 (A) has 5,345 MFI with SA beads, 352 MFI with the clean beads, and 7,625 MFI with the EB beads.2/13 (15%), 20/24 (83%), and 5/6 (83%) of the normal sera specificities <strong>for</strong> the A, B, and C locusrespectively are negative with the clean beads.[figure1]
Conclusions: Clean SA beads can eliminate “extra” reactions attributed to natural anti-HLA antibodies intransplant sera. Positive reactions with the SA beads become negative with the clean beads. Reactions ofnatural antibodies against exposed epitopes are not eliminated. Since their specificities are rare, have lowMFI, and share distinct epitopes, most can be identified. Clean beads have no effect on the reactivity ofalloantibodies and can potentially simplify sera analysis.El-Awar: One Lambda Inc.: Employee; Stockholder. Terasaki: One Lambda Inc.: Stockholder. Averly: OneLambda Inc.: Employee. Hopfield: One Lambda Inc.: Employee. Nguyen: One Lambda Inc.: Employee.13-PIMMUNOGENICITY OF HLA ANTIGENS.Hooi S. Eng, Inessa Kaplan, Mary S. Leffell, Andrea A. Zachary. Medicine, Johns Hopkins University,Baltimore, MD, USA.Aim: Solid phase immunoassays permit prediction of crossmatches (XMs) at different sensitivity levels.Knowledge about differing immunogenicity of HLA antigens could aid donor selection <strong>for</strong> transplantation.We examined antibodies predicted to yield positive XMs in 54 sensitized patients to those expected basedon equal antigen immunogenicity.Methods: Expected Ab frequencies were determined by: freq. of Ag in the donor population X (1- freq. ofAg in the patient population). Donor Ag frequencies were from the UNOS data base and recipient Ag freq.were calculated from the patient phenotypes.Results: Ten patients had antibodies to class I only (19%); 10 patients to class II only (19%) and 34patients had antibodies to both cI & cII (62%). Antibodies to DR were the most common (41/54, 76%),followed by B (37/54, 69%), A (35/54, 65%) and DQ (31/54, 57%). Anti-C antibodies were found in 2patients only and were excluded from further analysis. Of specificities observed, differences >10% betweenobserved and expected frequencies occurred in 9/11 (82%) A, 20/28 (71%) B, 5/10 (50%) DRB1, 1/3(33%) DRB345 and 2/4 (50%) DQ antigens. A10 (56%), A19 (56%), B15 (75%) and DR9 (36%) had thegreatest frequency differences. The specificities with 70% incidence) present at only the flowcytometric XM level.Conclusions: While differences in frequency may be due to immunogenicity, differences in antibodystrength may reflect repeated exposure to the more common antigens.14-PASSOCIATION BETWEEN DONOR SPECIFIC ANTIBODY (DSA) DETECTED BY SOLIDPHASE ASSAY (SpA) AND FLOW CYTOMETRIC CROSSMATCH (FXM).Manish J. Gandhi, Sandra Bryant, Rebekah M. Knauer, Lisa M. Hallaway, Steven R. DeGoey. MayoClinic, Rochester, MN, USA.Aim: Recipient DSA by SpA is used to screen donors as a surrogate <strong>for</strong> crossmatch as it is thought thatthere is good correlation between them. Association between 436 FXM and DSA from <strong>27</strong>3 unique pairswas studied.Methods: SpA was per<strong>for</strong>med by single antigen beads. Correlation between FXM mean channelshift(MCS) and DSA MFI were analyzed using MCS as the dependent variable and MFI as the independentvariable <strong>for</strong> 3 scenarios: 1.highest DSA(hDSA) 2.sum of DSA 3.each HLA DSA separately Generalizedestimating equations were used to assess these associations to properly adjust <strong>for</strong> the correlation structurewithin each pair, using an AR1 correlation structure within pairs. Models with the highest quasi-likelihoodunder the independence criterion(QIC) will provide the best-fitting models <strong>for</strong> this data. p-values
- Page 1 and 2: Monday, September 27, 20102:00 PM -
- Page 3 and 4: 5-ORTWO CASES OF DONOR SPECIFIC ANT
- Page 5 and 6: Monday, September 27, 20102:00 PM -
- Page 7 and 8: Results: PHA-induced mRNA expressio
- Page 9 and 10: conjugated IgM (BD Biosciences), Ig
- Page 11 and 12: Methods: Peripheral blood and endom
- Page 13 and 14: Aim: NK cells have an established r
- Page 15 and 16: Methods: Sera (n=22) were tested fo
- Page 17: expression on lymphocytes, we hypot
- Page 21 and 22: goal is to re-examine our previous
- Page 23 and 24: Aim: There is increasing evidence t
- Page 25 and 26: esult in poor graft survival. The g
- Page 27 and 28: Aim: Pronase treatment eliminates i
- Page 29 and 30: 34-PCLINICAL AND PATHOLOGICAL SIGNI
- Page 31 and 32: Nabil Mohsin, Isabelle G. Wood, Ind
- Page 33 and 34: donor/recipient pairs for transplan
- Page 35 and 36: and tested in the DynaChip assay fo
- Page 37 and 38: average difference between Ave and
- Page 39 and 40: Conclusions: The XM-One assay can b
- Page 41 and 42: 59-PCYTOTOXIC AND NON-CYTOTOXIC ANT
- Page 43 and 44: data suggests that DTT pretreatment
- Page 45 and 46: Bhavna Lavingia 1 , Chantale Lacell
- Page 47 and 48: ATG INTERFERNCE IN SINGLE ANTIGEN L
- Page 49 and 50: 75-PPREFORMED LOW REACTIVE ANTI-HLA
- Page 51 and 52: Sabarinathan Ramachandran 1 , Naohi
- Page 53 and 54: 83-PALLELIC DIVERSITY OF KIR2DL4 AN
- Page 55 and 56: São Paulo, Brazil; 3 Commissariat
- Page 57 and 58: 91-PCHARACTERIZATION OF COMMON AND
- Page 59 and 60: Conclusions: The extensive diversit
- Page 61 and 62: 99-PPOTENTIAL COMMON NOVEL ALLELES
- Page 63 and 64: 103-PTOWARDS A FUNCTIONAL HLA-DPB1
- Page 65 and 66: 107-PWHOLE GENOME AMPLIFICATION (WG
- Page 67 and 68: 111-PLOSS OF MISMATCHED HLA IN FAMI
- Page 69 and 70:
115-PDONOR EPITHELIAL CELL CHIMERIS
- Page 71 and 72:
Caucasian patients. MRs vary signif
- Page 73 and 74:
Results: We obtained the total No.
- Page 75 and 76:
cord blood and platelet transfusion
- Page 77 and 78:
131-PASSOCIATION OF IL-2-330(G/T) W
- Page 79 and 80:
Institute, Children’s Hospital Oa
- Page 81 and 82:
Methods: To prove the robustness of
- Page 83 and 84:
populations.We studied the involvem
- Page 85 and 86:
amplicons generated from different
- Page 87 and 88:
Results: The sequence of the unexpe
- Page 89 and 90:
concentration of the Taq Polymerase
- Page 91 and 92:
160-PASSOCIATION OF HAPLOTYPES WITH
- Page 93 and 94:
164-PDETECTION OF A DE NOVO DONOR S
- Page 95 and 96:
168-PA NOVEL HLA-DQB1 ALLELE CONFIR
- Page 97 and 98:
172-PSCREENING FOR HLA-SPECIFIC ALL
- Page 99 and 100:
176-PIMPLEMENTATION OF THE WORLD HE
- Page 101 and 102:
epertoire of displayed ligands and
- Page 103 and 104:
mucosa. No other samples were avail
- Page 105 and 106:
Conclusions: In previously reported
- Page 107 and 108:
Conclusions: Our findings can demon
- Page 109 and 110:
Conclusions: In analyzing this data
- Page 111 and 112:
examined on microarrays from a huma
- Page 113 and 114:
Methods: Serial analysis of sera ob
- Page 115 and 116:
Conclusions: These new technologies
- Page 117 and 118:
allograft injury. Four of these 18
- Page 119 and 120:
A NOVEL HLA CLASS I SINGLE ANTIGEN
- Page 121 and 122:
Results: Approximately twice as man
- Page 123:
Methods: Molecular HLA typing was p